Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Trial of NP-178 (Emoxipin) for the Treatment of Inflammatory Bowel Disease

Trial Profile

A Phase IIa Trial of NP-178 (Emoxipin) for the Treatment of Inflammatory Bowel Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emoxipin (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use

Most Recent Events

  • 29 Nov 2018 New trial record
  • 13 Nov 2018 According to a Nash Pharmaceuticals media release, the company plan to present preclinical in vivo IBD results at an upcoming conference and will update the market on plans for this phase IIa study for the leading repurposed IBD candidate NP-178 in 2019 pending additional results shortly.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top